Castle Biosciences (CSTL) Enterprise Value (2019 - 2026)

Castle Biosciences has disclosed Enterprise Value across 8 years of filings, most recently posting $460.8 million for Q2 2026.

• In Q2 2026, Enterprise Value rose 45.89% year-over-year to $460.8 million; the TTM figure through Jun 2026 stood at $460.8 million (up 45.89% YoY), while the FY2025 annual figure was $855.3 million, up 83.56% from the prior year.
• Enterprise Value came in at $460.8 million for Q2 2026 at Castle Biosciences, down from $482.0 million in the prior quarter.
• In the past five years, Enterprise Value ranged from a high of $855.3 million in Q4 2025 to a low of $141.9 million in Q2 2023.
• Average Enterprise Value over 5 years is $417.1 million, with a median of $373.0 million recorded in 2023.
• Year-over-year, Enterprise Value plunged 79.42% in 2022 and surged 142.04% in 2024.
• Over 5 years, Enterprise Value stood at $366.4 million in 2022, then retreated by 4.92% to $348.4 million in 2023, then surged by 33.73% to $465.9 million in 2024, then jumped by 83.56% to $855.3 million in 2025, then plunged by 46.12% to $460.8 million in 2026.
• Per Business Quant data, the three most recent Enterprise Value figures were $460.8 million in Q2 2026, $482.0 million in Q1 2026, and $855.3 million in Q4 2025.